🟡 60/100

Review before taking

  • Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

This product received a low safety score because its niacin content is more than 14 times the recommended daily upper limit of 35mg.

Label Data

1 Tablet(s) Serving Size
100 Servings
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

500 mg (3125% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 500mg UL 35mg

Other Ingredients

Vegetarian Stearine Cellulose Silicon Dioxide Magnesium Stearate Croscarmellose Sodium

Label Claims — Verification

All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested use: 1 tablet daily with food or as directed by a healthcare professional.

⚠️ Warnings & Precautions

Caution: If you are pregnant, nursing, have a medical condition, or taking prescription drugs, consult your healthcare professional before using this product.

Some forms of niacin may cause temporary flushing, tingling, itching, rash, or stomach upset. Consult your physician about periodic liver function testing if using this product long-term, or if you are taking more than 500 mg daily.

Keep out of reach of children.

Do not use if shrinkwrap is broken or missing.

🧪 Formulation Notes

Produced under a strict quality management system in compliance with good manufacturing practices (GMPs) and third-party quality certifications.

Additional Information

Store in a cool, dry place (59 degrees F - 86 degrees F) away from direct light.

To reorder visit Holtraceuticals.com

Product Details

UPC / SKU 8 28054 11613 9
DSLD Entry Date 2022-09-22
Product Type Vitamin
Form Tablet or Pill
DSLD ID 274446
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →